Leica Biosystems and Navinci join to accelerate cancer research

Leica Biosystems and Navinci, a leader in developing innovative solutions for studying protein interactions, have announced a strategic collaboration to drive innovation in cancer patient care. This partnership enables automated in situ proximity ligation assays on the BOND RX Fully Automated Research Stainer.

The use of spatial biology in translational research enables scientists to study tumour cells within their micro-environment and better understand cell-to-cell interactions. Navinci’s in situ proximity ligation assay extends the capabilities of traditional immunoassays to highlight protein interactions with high specificity and sensitivity such that the proximity and binding of one protein to another can be readily detected, localised and quantified.

The goal of the collaboration between Navinci and Leica Biosystems is to automate Navinci’s two new assay solutions on the BOND RX advanced staining platform in order to simplify and standardise the assay workflow for all laboratories and researchers. This integration provides researchers with a powerful platform to streamline their exploration of protein interactions involved in the tumour microenvironment and, ultimately, our understanding of cancer biology.

“Leica Biosystems joining forces with Navinci is critical making this powerful technology more widely accessible and available for cancer research,” shared Rob Monroe, Chief Medical Officer at Leica Biosystems. “The combination of our high-quality BOND RX Fully Automated Research Stainer with Navinci’s assay-based solutions empowers researchers to better understand the intricacies of tumour cell interactions, which will ultimately contribute to the identification of new targets for drug development and eventual new therapies for cancer patients.”

As part of this collaboration, Navinci is launching two groundbreaking products: NaveniBright BOND RX HRP and Naveni PD1/PD-L1 BOND RX. These are the first fully automated in situ proximity ligation assays designed to deliver enhanced reproducibility and throughput.

  • NaveniBright BOND RX HRP introduces a new assay, seamlessly integrating chromogenic readout automation on the Leica Biosystems BOND RX platform. Based on Navinci’s advanced Naveni in situ proximity ligation technology, this in situ kit provides flexibility tailored to customers’ primary antibodies and targets.
  • Naveni PD1/PD-L1 BOND RX addresses a critical need in immuno-oncology by enabling specific detection of PD1/PD-L1 interactions in situ. This capability improves reproducibility and throughput, allowing researchers to study this key immune checkpoint in larger cohorts.

For additional information about Navinci, Leica Biosystems, and the newly launched solutions, please visit www.leicabiosystems.com or www.navinci.se/technology/naveni-bond.


Latest Issues

The Power to Disrupt - Clinical Diagnostics Expo UK

15 Hatfields
16 September, 2024

Microbe Conference 2024

Crowne Plaza Hotel, Sheffield, UK
20-22 September, 2024

Cardiac Marker Dialogues: Cardiac Biomarkers in Real Time – Experiences and Opportunities

Hilton Glasgow, 1 William Street, Glasgow, Scotland, G3 8HT
26-27 September, 2024

The British Association for Cytopathology Annual Scientific Meeting

Aztec Hotel and Spa, Bristol, BS32 4TS
18 October, 2024

UK NEQAS: Navigating Quality Standards in Point of Care Testing

The Hyatt Regency Hotel, Birmingham, UK
23 October, 2024